COMPASS Pathways plc

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment a.

businesswire.com - 2026-07-16 06:35:00

Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...

proactiveinvestors.com - 2026-07-15 11:34:00

CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...

proactiveinvestors.com - 2026-07-14 07:53:00

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...

proactiveinvestors.com - 2026-07-14 07:20:00

Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.

marketbeat.com - 2026-07-10 03:03:16

Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission

seekingalpha.com - 2026-07-08 13:23:52

COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

seekingalpha.com - 2026-07-07 17:32:28

Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for treatment-resistant depression (TRD).

benzinga.com - 2026-07-07 12:24:36

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360's rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported resul.

businesswire.com - 2026-07-07 06:30:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of emplo.

businesswire.com - 2026-07-02 06:30:00

Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. NEW YORK and TORONTO, June 26, 2026 /PRNewswire/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule.

prnewswire.com - 2026-06-26 09:30:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of.

businesswire.com - 2026-06-05 06:30:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding bio.

businesswire.com - 2026-05-28 06:30:00

COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary endpoint success in Phase 3 trials, with potential for less frequent dosing and improved convenience over Spravato, the current TRD market leader. My fair value estimate for CMPS is $13.63 per share, probability-weighted for FDA approval, with upside to $18.65 if approved and downside to $6.96 if a CRL is issued.

seekingalpha.com - 2026-05-27 08:39:33

Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timeline.

marketbeat.com - 2026-05-21 02:03:50

Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment-resistant depression market, leveraging regulatory tailwinds and growing psychiatric support for psychedelics. COMP360's rapid onset and durability should see it become an important option for TRD patients.

seekingalpha.com - 2026-05-14 20:36:14

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced

gurufocus.com - 2026-05-14 07:00:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A repla.

businesswire.com - 2026-05-14 06:30:00

COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 16:00:50

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in treatment-resistant depression. For the quarter, Compass reported an adjusted loss of $0.30 per share, coming in ahead of analyst expectations of a loss per share of $0.43.

proactiveinvestors.com - 2026-05-13 12:34:55

Compass Pathways NASDAQ: CMPS said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved.

marketbeat.com - 2026-05-13 10:08:08

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for...

proactiveinvestors.com - 2026-05-13 08:33:00

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today repo

gurufocus.com - 2026-05-13 07:00:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights. “With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways.

businesswire.com - 2026-05-13 06:30:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass P.

businesswire.com - 2026-05-06 06:30:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of em.

businesswire.com - 2026-05-06 06:25:00

Pre-Market Stock Futures: Futures are trading lower as we start off the new week, as oil surges higher amid reports that a U.S. warship was turned back in the Strait of Hormuz, but what a start we had to the new month on Friday. The Thursday close on April's last trading day marked the best... Here Are Monday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, Internatioinal Paper, Trade Desk, and More

247wallst.com - 2026-05-04 07:54:25

The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile domestic political news stories, but the implications for this small but growing industry are tremendous. Indeed, within days, the FDA began to make moves, awarding national priority vouchers to select companies developing drugs in this category, thereby reducing drug review times considerably.

marketbeat.com - 2026-04-27 11:15:52

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

zacks.com - 2026-04-24 10:41:24

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass' proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for th.

businesswire.com - 2026-04-24 10:37:00

Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.

fool.com - 2026-04-23 21:50:00

Does COMPASS Pathways PLC Sponsored ADR (CMPS) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-04-22 13:01:25

The mean of analysts' price targets for COMPASS Pathways (CMPS) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-04-22 10:56:08

Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge gains in three market days after White House announcement. The investment thesis previously emphasized exciting prospects, but risk factors had dominated recent performance prior to White House action.

seekingalpha.com - 2026-04-21 11:45:00

FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...

proactiveinvestors.com - 2026-04-21 09:48:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further exp.

businesswire.com - 2026-04-21 06:30:00

While many investors focused on the annual 4/20 holiday, expecting the usual buzz around marijuana stocks, a quiet revolution was unfolding in Washington. Over a weekend when most of the market was logged off, the administration issued a bombshell executive order designed to fast-track psychedelic medicines to market.

marketbeat.com - 2026-04-20 15:05:42

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status, but reinforces a federal move toward medical, evidence-based framework for other alternative medicines, like cannabis, experts say.

cnbc.com - 2026-04-20 14:05:39

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for approval.

fool.com - 2026-04-20 12:02:35

COMPASS Pathways plc is developing pharmaceutical-grade psilocybin treatments for severe mental health conditions, notably treatment-resistant depression. CMPS remains a pipeline-stage biotech with no current sales, as its lead product, COMP360, is still in clinical trials. A recent executive order aims to accelerate access to psychedelic drug research and treatments, potentially benefiting CMPS's regulatory pathway.

seekingalpha.com - 2026-04-20 11:26:58

The FDA will fast-track certain psychedelic treatments. Several biotech stocks are soaring due to the new policy.

fool.com - 2026-04-20 11:07:47

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of.

businesswire.com - 2026-04-20 06:30:00

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...

proactiveinvestors.com - 2026-04-20 05:56:00

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration's Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h.

businesswire.com - 2026-04-18 16:12:00